PHIO
Phio Pharmaceuticals Corp.
Price Chart
Latest Quote
$1.06
+0.03 (+2.44%)
Current Price
| Previous Close | $1.03 |
| Open | $1.04 |
| Day High | $1.08 |
| Day Low | $1.04 |
| Volume | 175,850 |
Stock Information
| Shares Outstanding | 11.62M |
| Cash Equivalents | $17.03M |
| Net Income | $-10.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12.26M |
| EPS (TTM) | $-1.35 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-5.07M |
| Income | $-10.93M |
| Book/sh | $1.42 |
| Cash/sh | $1.47 |
| Employees | 6 |
Financial Ratios
| Quick Ratio | 17.93 |
| Current Ratio | 18.32 |
Returns & Margins
| ROA | -46.65% |
| ROE | -76.36% |
Ownership
| Insider Ownership | 1.93% |
| Institutional Ownership | 10.82% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.23 |
| P/B | 0.74 |
Analyst Data
| Recommendation | none |
| Target Price | $14.00 |
Technical Indicators
| SMA20 | $1.09 |
| SMA50 | $1.14 |
| SMA200 | $1.39 |
| RSI | 40.28 |
| ATR | 0.0503 |
| Shares Float | 11.55M |
| Short Float | 2.71% |
| Short Ratio | 2.24 |
| Volatility | 0.81 |
| Rel Volume | 1.12 |
Performance History
| Week | -1.39% |
| Month | -2.31% |
| Quarter | -13.52% |
| 6 Months | -1.39% |
| YTD | -3.20% |
| Year | -55.29% |
| 3 Years | -96.28% |
| 5 Years | -99.59% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.06 | 175,870 |
| 2026-06-18 | $1.03 | 257,200 |
| 2026-06-17 | $1.08 | 146,100 |
| 2026-06-16 | $1.06 | 191,100 |
| 2026-06-15 | $1.10 | 210,900 |
| 2026-06-12 | $1.07 | 103,900 |
| 2026-06-11 | $1.08 | 177,700 |
| 2026-06-10 | $1.06 | 192,300 |
| 2026-06-09 | $1.08 | 177,200 |
| 2026-06-08 | $1.09 | 225,400 |
| 2026-06-05 | $1.06 | 126,400 |
| 2026-06-04 | $1.14 | 91,700 |
| 2026-06-03 | $1.11 | 55,800 |
| 2026-06-02 | $1.12 | 100,500 |
| 2026-06-01 | $1.13 | 262,300 |
| 2026-05-29 | $1.11 | 101,600 |
| 2026-05-28 | $1.14 | 112,300 |
| 2026-05-27 | $1.10 | 136,600 |
| 2026-05-26 | $1.08 | 183,700 |
| 2026-05-22 | $1.09 | 115,900 |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
đ° Latest News
BC-Most Active Stocks
Associated Press Finance âĸ 2026-02-10T15:30:23ZAsian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
MT Newswires âĸ 2025-12-18T15:41:09ZPhio Reports Tumor Responses in PH-762 Phase 1b Cancer Trial; Shares Surge
MT Newswires âĸ 2025-07-25T17:54:48Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $9,220,000 | $7,387,000 | $10,698,000 | $11,462,000 |
| Other Income Expense | $2,000 | $6,000 | $-120,000 | $-18,000 |
| Other Non Operating Income Expenses | $2,000 | $6,000 | $6,000 | $-18,000 |
| Net Non Operating Interest Income Expense | $520,000 | $231,000 | $-8,000 | - |
| Total Other Finance Cost | $-520,000 | $-231,000 | $8,000 | - |
| Operating Expense | $9,220,000 | $7,387,000 | $10,698,000 | $11,462,000 |
| General And Administrative Expense | $4,602,000 | $3,744,000 | $4,366,000 | $4,450,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Net Interest Income | $520,000 | $231,000 | $-8,000 | - |
| Normalized Income | $-8,698,000 | $-7,150,000 | $-10,700,000 | $-11,480,000 |
| Net Income From Continuing And Discontinued Operation | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Total Operating Income As Reported | $-9,220,000 | $-7,387,000 | $-10,824,000 | $-11,462,000 |
| Net Income Common Stockholders | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Net Income | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Net Income Including Noncontrolling Interests | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Net Income Continuous Operations | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Pretax Income | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Operating Income | $-9,220,000 | $-7,387,000 | $-10,698,000 | $-11,462,000 |
| Special Income Charges | - | $0 | $-126,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.45 | $-9.08 | $-46.76 | $-90.86 |
| Basic EPS | $-1.45 | $-9.08 | $-46.76 | $-90.86 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,217,000 | $-7,352,000 | $-10,388,000 | $-11,269,000 |
| Reconciled Depreciation | $3,000 | $35,000 | $184,000 | $193,000 |
| EBITDA (Bullshit earnings) | $-9,217,000 | $-7,352,000 | $-10,514,000 | $-11,269,000 |
| EBIT | $-9,220,000 | $-7,387,000 | $-10,698,000 | $-11,462,000 |
| Diluted Average Shares | $5,984,017 | $787,466 | $231,508 | $126,335 |
| Basic Average Shares | $5,984,017 | $787,466 | $231,508 | $126,335 |
| Diluted NI Availto Com Stockholders | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Research And Development | $4,618,000 | $3,643,000 | $6,332,000 | $7,012,000 |
| Selling General And Administration | $4,602,000 | $3,744,000 | $4,366,000 | $4,450,000 |
| Other Gand A | $4,602,000 | $3,744,000 | $4,366,000 | $4,450,000 |
| Total Unusual Items | - | $0 | $-126,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-126,000 | $0 |
| Impairment Of Capital Assets | - | $0 | $126,000 | $0 |
| Tax Provision | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Total Assets | $21,487,000 | $5,738,000 | $9,364,000 | $12,814,000 |
| Total Non Current Assets | $11,000 | $2,000 | $42,000 | $368,000 |
| Current Assets | $21,476,000 | $5,736,000 | $9,322,000 | $12,446,000 |
| Other Current Assets | $445,000 | $354,000 | $832,000 | $615,000 |
| Cash Cash Equivalents And Short Term Investments | $21,031,000 | $5,382,000 | $8,490,000 | $11,781,000 |
| Cash And Cash Equivalents | $21,031,000 | $5,382,000 | $8,490,000 | $11,781,000 |
| Cash Financial | $21,031,000 | $5,382,000 | $8,490,000 | $11,781,000 |
| Other Non Current Assets | - | - | $3,000 | $24,000 |
| Restricted Cash | - | - | $0 | $50,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | $0 | $35,000 | $170,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $35,000 |
| Current Debt And Capital Lease Obligation | - | - | $35,000 | $135,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,340,000 | $1,015,000 | $1,634,000 | $1,976,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $37,000 |
| Current Liabilities | $1,340,000 | $1,015,000 | $1,634,000 | $1,939,000 |
| Payables And Accrued Expenses | $1,340,000 | $1,015,000 | $1,377,000 | $1,396,000 |
| Payables | $435,000 | $253,000 | $657,000 | $779,000 |
| Accounts Payable | $435,000 | $253,000 | $657,000 | $779,000 |
| Other Current Liabilities | - | - | - | $19,000 |
| Equity | ||||
| Common Stock Equity | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Total Equity Gross Minority Interest | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Stockholders Equity | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Retained Earnings | $-155,054,000 | $-146,356,000 | $-139,206,000 | $-128,380,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $0 | $2,000 |
| Other | ||||
| Ordinary Shares Number | $11,617,250 | $1,732,411 | $416,369 | $126,558 |
| Share Issued | $11,617,250 | $1,732,411 | $416,369 | $126,558 |
| Tangible Book Value | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Invested Capital | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Working Capital | $20,136,000 | $4,721,000 | $7,688,000 | $10,507,000 |
| Total Capitalization | $20,147,000 | $4,723,000 | $7,730,000 | $10,838,000 |
| Additional Paid In Capital | $175,200,000 | $151,079,000 | $146,936,000 | $139,218,000 |
| Capital Stock | $1,000 | $0 | $0 | $0 |
| Common Stock | $1,000 | $0 | $0 | $0 |
| Current Accrued Expenses | $905,000 | $762,000 | $720,000 | $617,000 |
| Net PPE | $11,000 | $2,000 | $39,000 | $344,000 |
| Accumulated Depreciation | $-228,000 | $-306,000 | $-1,136,000 | $-1,175,000 |
| Gross PPE | $239,000 | $308,000 | $1,175,000 | $1,519,000 |
| Machinery Furniture Equipment | $239,000 | $308,000 | $1,096,000 | $1,312,000 |
| Capital Lease Obligations | - | $0 | $35,000 | $170,000 |
| Current Capital Lease Obligation | - | $0 | $35,000 | $135,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $31,000 | $222,000 | $408,000 |
| Leases | - | $0 | $46,000 | $46,000 |
| Properties | - | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | - | $0 | $35,000 |
| Other Properties | - | - | $33,000 | $161,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,991,000 | $-7,113,000 | $-10,754,000 | $-12,250,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,979,000 | $-7,112,000 | $-10,749,000 | $-12,129,000 |
| Cash Flow From Continuing Operating Activities | $-7,979,000 | $-7,112,000 | $-10,749,000 | $-12,129,000 |
| Operating Gains Losses | - | $-6,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-12,000 | $-1,000 | $-5,000 | $-121,000 |
| Investing Cash Flow | $-12,000 | $8,000 | $-5,000 | $-121,000 |
| Cash Flow From Continuing Investing Activities | $-12,000 | $8,000 | $-5,000 | $-121,000 |
| Net Other Investing Changes | - | $9,000 | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-1,000 | $-13,000 | $0 |
| Issuance Of Capital Stock | $17,915,000 | $0 | $7,452,000 | $2,000 |
| Financing Cash Flow | $23,640,000 | $3,996,000 | $7,413,000 | $-26,000 |
| Cash Flow From Continuing Financing Activities | $23,640,000 | $3,996,000 | $7,413,000 | $-26,000 |
| Net Other Financing Charges | $-30,000 | $-5,000 | $-26,000 | $-28,000 |
| Net Common Stock Issuance | $17,915,000 | $-1,000 | $7,441,000 | $0 |
| Common Stock Issuance | $17,915,000 | $0 | $7,452,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $-2,000 | $2,000 |
| Preferred Stock Issuance | - | - | $0 | $2,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $13,000 | $11,000 | - |
| End Cash Position | $21,031,000 | $5,382,000 | $8,490,000 | $11,831,000 |
| Beginning Cash Position | $5,382,000 | $8,490,000 | $11,831,000 | $24,107,000 |
| Changes In Cash | $15,649,000 | $-3,108,000 | $-3,341,000 | $-12,276,000 |
| Proceeds From Stock Option Exercised | $5,755,000 | $4,002,000 | - | $0 |
| Common Stock Payments | $0 | $-1,000 | $-11,000 | $0 |
| Net PPE Purchase And Sale | $-12,000 | $-1,000 | $-5,000 | $-121,000 |
| Purchase Of PPE | $-12,000 | $-1,000 | $-5,000 | $-121,000 |
| Change In Working Capital | $235,000 | $-138,000 | $-536,000 | $-1,256,000 |
| Change In Other Current Liabilities | $0 | $-35,000 | $-135,000 | $-125,000 |
| Change In Payables And Accrued Expense | $326,000 | $-584,000 | $-205,000 | $-1,139,000 |
| Change In Accrued Expense | $143,000 | $-180,000 | $-83,000 | $-1,635,000 |
| Change In Payable | $183,000 | $-404,000 | $-122,000 | $496,000 |
| Change In Account Payable | $183,000 | $-404,000 | $-122,000 | $496,000 |
| Change In Prepaid Assets | $-91,000 | $481,000 | $-196,000 | $8,000 |
| Stock Based Compensation | $481,000 | $147,000 | $303,000 | $414,000 |
| Depreciation Amortization Depletion | $3,000 | $35,000 | $184,000 | $193,000 |
| Depreciation And Amortization | $3,000 | $35,000 | $184,000 | $193,000 |
| Depreciation | $3,000 | $35,000 | $184,000 | $193,000 |
| Gain Loss On Sale Of PPE | $0 | $-6,000 | $0 | - |
| Net Income From Continuing Operations | $-8,698,000 | $-7,150,000 | $-10,826,000 | $-11,480,000 |
| Preferred Stock Payments | - | $0 | $-2,000 | $0 |
| Asset Impairment Charge | - | $0 | $126,000 | $0 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-22